After previously being shown to reduce disease progression in mouse models of lupus, a drug comprising inactivated interferon-α (IFN-α) coupled to a carrier molecule was tested in a phase I–II study of 28 women with systemic lupus erythematosus. All immunized patients produced anti-IFN-α antibodies, titres of which correlated with baseline expression of IFN-α-induced genes. The antibody response in patients who expressed IFN-α-induced genes at baseline was associated with reduced expression of those genes, and with recovery of serum levels of complement C3.
ORIGINAL RESEARCH PAPER
Lauwerys, B. R. et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum. doi:10.1002/art.37785
Rights and permissions
About this article
Cite this article
Immunization of patients with SLE with IFN. Nat Rev Rheumatol 9, 64 (2013). https://doi.org/10.1038/nrrheum.2012.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.229
